ReviewInternational journal of molecular sciences2026
Iron Deficiency in Pulmonary Hypertension-Prevalence, Impact on Prognosis and Disease Burden in Pulmonary Arterial Hypertension and Pulmonary Hypertension Related to Hypoxia: A Review.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron Compartmentalisation and Vascular Endothelial Cell Dysfunction.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) is recognized for being a severe, chronic phenomenon that necessitates a careful multidisciplinary approach. Its frequent coexistence with multiple comorbidities highlights the need for tailored decision-making concerning treatment towards not only certain PH subtypes but also towards each individual patient as well. Pulmonary arterial hypertension (PAH) management has undergone extensive development, which enabled patients' life expectancy to be prolonged. The targeted treatment made a significant contribution to the improvement of the patients' quality of life, thereby reducing the illness burden. However, apart from the administration of drugs in the course of PAH, there is also the field for determining and addressing modifiable factors, which may influence everyday life and the final outcome of these individuals. Taking into consideration the fact that iron deficiency (ID) is the most prevalent nutritional deficit worldwide and that there exists a well-established, scientifically supported correlation between ID and the outcome and prognosis of left heart failure patients, multiple studies were conducted in order to verify a possible connection between ID and right heart failure as well. Indeed, the crossroads of iron and PAH, PH related to hypoxia, and pathophysiological mechanisms linking pulmonary vasculature and ID have been eagerly investigated over recent years. Therefore, research provided a considerable amount of data in this area, emphasizing the potential usefulness of iron homeostasis to serve as a prognostic factor. Nevertheless, due to extensive exploration of this matter, several issues have arisen that demand further study and clarification, with the use of a proper ID definition being one of the most crucial. Herein, we present a concise review of the most up-to-date literature regarding iron's homeostasis and pulmonary vascular bed through the prism of PAH and PH related to hypoxia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.